{
    "organizations": [],
    "uuid": "07942d9c5e8e82f3fc37846c395b74a3a9ddc03f",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/22/globe-newswire-oncomed-pharmaceuticals-to-report-fourth-quarter-and-full-year-2017-financial-results-and-operational-highlights-on-march.html",
    "ord_in_thread": 0,
    "title": "OncoMed Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights on March 8th, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "REDWOOD CITY, Calif., OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that the Company will report fourth quarter and full year 2017 financial results and operational highlights on Thursday, March 8th, 2018. OncoMed management will host a conference call and webcast at 4:30 p.m. Eastern Time (ET) / 1:30 p.m. Pacific Time (PT).\nAnalysts and investors can participate in the conference call by dialing (855) 420-0692 (domestic) and (484) 756-4194 (international) using the conference ID# 4997704. The webcast of the conference call can be accessed live on the Investor Relations section of the OncoMed website, http://www.oncomed.com , and will be available for replay through June 30th, 2018.\nAn audio replay of the conference call can be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international) utilizing the conference ID number listed above.\nAbout OncoMed Pharmaceuticals\nOncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics. OncoMed has internally discovered a broad pipeline of investigational drugs intended to address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. Navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83), rosmantuzumab (anti-RSPO3, OMP131-R10) and anti-TIGIT (OMP-313M32) are part of OncoMed's strategic alliance with Celgene Corporation. OncoMed is independently developing GITRL-Fc (OMP-336B11), as well as continuing to pursue new drug discovery research. For further information about OncoMed Pharmaceuticals, please see www.oncomed.com .\nInvestor Relations Contact:\nPeter Rahmer\nTrout Group\nprahmer@troutgroup.com\n(646) 378-2973\nMike Zanoni\nTrout Group\nmzanoni@troutgroup.com\n(646) 378-2924\nSource:OncoMed Pharmaceuticals, Inc.",
    "published": "2018-02-23T00:02:00.000+02:00",
    "crawled": "2018-02-23T01:52:22.009+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "redwood",
        "city",
        "oncomed",
        "pharmaceutical",
        "nasdaq",
        "omed",
        "biopharmaceutical",
        "company",
        "focused",
        "discovering",
        "developing",
        "novel",
        "therapeutic",
        "today",
        "announced",
        "company",
        "report",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "operational",
        "highlight",
        "thursday",
        "march",
        "8th",
        "oncomed",
        "management",
        "host",
        "conference",
        "call",
        "webcast",
        "eastern",
        "time",
        "et",
        "pacific",
        "time",
        "pt",
        "analyst",
        "investor",
        "participate",
        "conference",
        "call",
        "dialing",
        "domestic",
        "international",
        "using",
        "conference",
        "id",
        "webcast",
        "conference",
        "call",
        "accessed",
        "live",
        "investor",
        "relation",
        "section",
        "oncomed",
        "website",
        "http",
        "available",
        "replay",
        "june",
        "30th",
        "audio",
        "replay",
        "conference",
        "call",
        "accessed",
        "dialing",
        "domestic",
        "international",
        "utilizing",
        "conference",
        "id",
        "number",
        "listed",
        "oncomed",
        "pharmaceutical",
        "oncomed",
        "pharmaceutical",
        "biopharmaceutical",
        "company",
        "focused",
        "discovering",
        "developing",
        "novel",
        "therapeutic",
        "oncomed",
        "internally",
        "discovered",
        "broad",
        "pipeline",
        "investigational",
        "drug",
        "intended",
        "address",
        "fundamental",
        "biology",
        "driving",
        "cancer",
        "growth",
        "resistance",
        "recurrence",
        "metastasis",
        "navicixizumab",
        "bispecific",
        "rosmantuzumab",
        "part",
        "oncomed",
        "strategic",
        "alliance",
        "celgene",
        "corporation",
        "oncomed",
        "independently",
        "developing",
        "well",
        "continuing",
        "pursue",
        "new",
        "drug",
        "discovery",
        "research",
        "information",
        "oncomed",
        "pharmaceutical",
        "please",
        "see",
        "investor",
        "relation",
        "contact",
        "peter",
        "rahmer",
        "trout",
        "group",
        "prahmer",
        "mike",
        "zanoni",
        "trout",
        "group",
        "mzanoni",
        "source",
        "oncomed",
        "pharmaceutical",
        "inc"
    ]
}